Andrew Rashkow

Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators.

Hertzel C. Gerstein, Johannes F.E. Mann, Janice Pogue et al. · PubMed · 2000 · 154 citations

The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events

F Mindlen, Roberto Nordaby, M I Soto Ruiz et al. · Queensland's institutional digital repository (The University of Queensland) · 1996 · 154 citations

Non-pharmacological Intervention, Preventive Medicine, Cardiovascular Disease +10

Development of Renal Disease in People at High Cardiovascular Risk

Johannes F.E. Mann, Hertzel C. Gerstein, Qilong Yi et al. · Journal of the American Society of Nephrology · 2003 · 142 citations

What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker?

Lars Gullestad, John Wikstrand, Prakash Deedwania et al. · Journal of the American College of Cardiology · 2005 · 106 citations

Heart Rate, Heart Failure, Cardiovascular Disease +6

Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study

Johannes F.E. Mann, Hertzel C. Gerstein, Qilong Yi et al. · American Journal of Kidney Diseases · 2003 · 84 citations

Hemodialysis, Urology, Renal Disease +13